The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

TCR-based Therapies Market by Target Indications (Bladder Cancer, Multiple Myeloma, Ovarian Cancer, Nasopharyngeal Carcinoma, Acute Myeloid Leukemia and Sarcoma), Target Antigens (NY-ESO-1, p53, WT-1 and EBV), Key Players and Key Geographies (North America, Europe and Asia Pacific), Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    March 2021

  • Pages
    397

  • View Count
    2242

Example Insights

TCR-based-Therapies-Market-Context TCR-based-Therapies-Market-Social-Media-Analysis TCR-based-Therapies-Market-Development-Pipeline TCR-based-Therapies-Market-Distribution-by-Source-of-T-Cells
TCR-based-Therapies-Market-Distribution-by-Indication TCR-based-Therapies-Market-Regional-Distribution TCR-based-Therapies-Market-List-Of-Cell-Therapy-Manufacturers TCR-based-Therapies-Market-Partnerships-and-Collaborations
TCR-based-Therapies-Market-Funding-and-Investments TCR-based-Therapies-Market-Future-Forecast    

 

Overview

The inherent heterogeneity of cancer cells and the immunosuppressive properties of the tumor microenvironment make it difficult to design viable and effective therapeutics against oncological disorders. However, targeted cell-based immunotherapies have demonstrated significant potential in treating patients suffering from cancer. Modified T-cell receptor (TCR)-based therapies, an upcoming class of cell-based interventions, is a promising therapeutic modality. Their tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor cells from the body of a host, with negligible treatment-related side effects. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors. Similar to other T-cell based interventions (such as CAR-T cells and TILs), TCR therapies are designed to target the underlying causes (or primary mediators) of a clinical condition. Additionally, this emerging class of biologics is believed to possess the potential to cater to unmet pharmacological needs across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate. The contemporary TCR-based therapies market is characterized by a healthy and growing pipeline of close to 150 candidate therapies. More than 15 such therapies, including GSK3377794 (GlaxoSmithKline), IMCgp100 (Immunocore), YT-E001 (China Immunotech Biotechnology) and ADP-A2M4 (Adaptimmune Therapeutics), are in the advanced stages of development. 

Presently, more than 100 industry and non-industry players, across the globe claim to be engaged in the development and clinical evaluation of antigen sensitized TCR-based cell therapies. The growing interest in this field is reflected in the notable increase in partnership activity (close to 120 deals inked in the past decade alone; CAGR 29%), between various industry players and academic / research institutes. Mostly driven by the need for effective treatment options for cancer, the TCR-based therapy pipeline is expected to continue to steadily grow over the coming years. Moreover, clinical success is likely to draw in investments that will support ongoing and anticipated therapy development initiatives. Overall, we are led to believe that the global TCR-based therapies market is poised to witness significant growth in the foreseen future.

Scope of the Report

The “TCR-based Therapies Market by Target Indications (Bladder Cancer, Multiple Myeloma, Ovarian Cancer, Nasopharyngeal Carcinoma, Acute Myeloid Leukemia and Sarcoma), Target Antigens (NY-ESO-1, p53, WT-1 and EBV), Key Players (GlaxoSmithKline, Adaptimmune Therapeutics, Merck, Altor Bioscience, Juno Therapeutics and Takara Bio) and Key Geographies (North America, Europe and Asia Pacific) – Global Forecast 2021-2030” report features an extensive study of the current market landscape and future potential of TCR-based therapies. The report highlights the efforts of both industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape of TCR-based therapies with respect to type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II and phase II,), therapeutic area (hematological cancer, solid tumor and others), popular target indications (lung cancer, melanoma, liver cancer, acute myeloid leukemia, ovarian cancer, multiple myeloma, sarcoma, head and neck cancer, bladder cancer, myelodysplastic syndrome, stomach cancer, pancreatic cancer, brain cancer, acute lymphoblastic leukemia, esophageal cancer and others), popular target antigen (NY-ESO-1, HBV, WT-1, HPV, MAGE-A4, KRAS, p53, PRAME, AFP, CD19, gp100, HPV E6, LAGE-1a, MART-1, Meso and others), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and elderly patients), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates) engaged in this domain. 
  • Detailed profiles of clinical products in developmental stages (phase I/II or above); each profile features an overview of the therapy, its mechanism of action,  clinical development plan, key clinical trial results and dosage information.
  • A detailed target antigen analysis, taking into consideration the number of TCR-based therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.
  • An analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 analysis assessing the relative experience of KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) in this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers engaged in the development of TCR-based therapies.
  • An overview of the focus therapeutic areas of drug developers, including an assessment of the opportunity (in terms of revenue generation potential from therapy sales) across oncological disease indications.
  • An analysis of the partnerships that have been established in the recent past, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of investments that have been made into companies which have proprietary, TCR-based products / technologies. The various type of funding instances reported in this domain include seed financing, venture capital financing, capital raised from IPOs and subsequent public offerings, grants, and debt financing.
  • A case study on manufacturing of cell therapy products, highlighting the key challenges associated with the production of such therapies. In addition, it features a detailed list of contract service providers and in-house manufacturers engaged in this market.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may adopt, in order to decide the price of a TCR-based therapy.
  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, highlighting the yearly trend of tweets, most frequently talked about product candidates, popular disease indications, target antigens, as well as prolific authors and social media influencers.
  • A review of the key promotional strategies that have been adopted by developers of marketed T-cell therapies, namely KYMRIAH® and YESCARTA®.

One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for TCR-based therapies over the coming decade. Based on several parameters, such as target consumer segments, region specific adoption rates and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2021-2030. The report also includes likely sales forecasts of TCR-based therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TCR-based therapies market, wherein both the current and upcoming opportunity is segmented across [A] target indications (bladder cancer, multiple myeloma, ovarian cancer, nasopharyngeal carcinoma, acute myeloid leukemia and sarcoma), [B] target antigens (NY-ESO-1, p53, WT-1 and EBV), [C] key players (GlaxoSmithKline, Adaptimmune Therapeutics, Merck, Altor Bioscience, Juno Therapeutics and Takara Bio) and [D] key geographies (North America, Europe, Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Miguel Forte (Chief Operating Officer, TxCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • What are the prevalent R&D trends related to TCR-based therapies?
  • What are the key therapeutic areas for which TCR-based therapies are being / have been developed?
  • What are the challenges commonly faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players engaged in the development of TCR-based therapies?
  • Across which geographies, extensive research related to TCR-based therapies is being conducted?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts engaged in this upcoming field of therapeutics?
  • What type of partnership models are commonly adopted by industry stakeholders? 
  • Across which regions is contract manufacturing support available for TCR-based therapies?
  • Which type of promotional strategies are likely to be adopted for TCR-based therapies that are approved or likely to be commercialized in the future?
  • Which factors are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments? 

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the TCR-based therapies market in the short to mid-term and long term.

Chapter 3 provides a general overview of TCR-based therapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of TCR-based therapies, factors supporting the growing popularity of TCR-based therapies and the challenges associated with such products. 

Chapter 4 provides insights on the popularity of TCR-based therapies on the social media platform, Twitter. The section highlights the yearly distribution of tweets posted on the platform in the time period 2012-2019, and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most frequently talked about product candidates, popular disease indications, target antigens, and prolific authors and social media influencers.

Chapter 5 includes detailed assessment on more than 145 TCR-based therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry / non-industry), phase of development (preclinical, phase I, phase I/II and phase II), therapeutic area (hematological cancer, solid tumor and others), popular target indications (lung cancer, melanoma, liver cancer, acute myeloid leukemia, ovarian cancer, multiple myeloma, sarcoma, head and neck cancer, bladder cancer, myelodysplastic syndrome, stomach cancer, pancreatic cancer, brain cancer, acute lymphoblastic leukemia, esophageal cancer and others), popular target antigen (NY-ESO-1, HBV, WT-1, HPV, MAGE-A4, KRAS, p53, PRAME, AFP, CD19, gp100, HPV E6, LAGE-1a, MART-1, Meso and others), source of T-cells (autologous / allogeneic), route of administration (intravenous, intratumor, intraperitoneal, intrapleural, intraventricular and others), dose frequency (single dose, multiple dose and split dose), target patient segment (children, adults and elderly patients), and type of therapy (monotherapy and combination therapy). Further, the chapter provides a list of the most active players (in terms of number of pipeline candidates). 

Chapter 6 presents a collection of key insights derived from the target antigen analysis. It includes a bubble analysis highlighting the most popular targets of TCR-based therapies in hematological cancer and solid tumor space. 

Chapter 7 features an analysis highlighting the key opinion leaders (KOLs) in this domain. It features a 2×2 matrix based representation highlighting the KOLs shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field, and a schematic world map representation, indicating the geographical location of eminent scientists / researchers involved in the development of TCR-based therapies.

Chapter 8 provides detailed profiles of TCR-based therapies in developmental stages (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, clinical development plan, and key clinical trial results.

Chapter 9 identifies the most commonly targeted therapeutic indications, including hematological cancers and solid tumors and features brief discussions on the TCR-based therapies being developed against them. The section also highlights key epidemiological facts and the currently available treatment options for each indication.

Chapter 10 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed based on various parameters, such as type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 11 provides details on the various investments and grants that have been awarded to players focused on the development of TCR-based therapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 12 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. It includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 13 highlights our views on the various factors that must be taken into consideration while deciding the prices of TCR-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their TCR-based therapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for CAR-T cell therapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of for CAR-T cell therapies.

Chapter 14 features an elaborate discussion on the future commercial opportunity offered by TCR-based therapies. It provides a comprehensive market forecast analysis for molecules that are approved or are in phase I/II and phase II of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] target indications (bladder cancer, multiple myeloma, ovarian cancer, nasopharyngeal carcinoma, acute myeloid leukemia and sarcoma), [B] target antigens (NY-ESO-1, p53, WT-1 and EBV) and [C] key geographies (North America, Europe and Asia Pacific).

Chapter 15 highlights the key promotional strategies that are being implemented by the developers of the marketed products, KYMRIAH® and YESCARTA®. The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 16 includes brief company profiles of the leading players in the TCR-based therapy market. Each company profile includes an overview of the developer and brief description of the product portfolio specific to technology portfolio (if available), recent developments related to TCR-based therapy and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 17 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Chief Executive Officer, Cell Therapies), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Miguel Forte (Chief Operating Officer, TxCell), and Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 20 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapy
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy

3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies

3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution of T-Cell Immunotherapies
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing Process of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods

3.7. T-Cell Receptor (TCR)-based Cell Therapy
3.7.1. History of Development
3.7.2. Anatomical Layout of TCR
3.7.3. Development of TCR-based Therapies
3.7.4. Comparison of CAR-T and TCR-based Therapies
3.7.5. Challenges Associated with TCR-based Therapies
3.7.6. Key Challenges and Roadblocks
3.7.7. Concluding Remarks

4. EMERGING TRENDS ON SOCIAL MEDIA
4.1. Chapter Overview
4.2. TCR-based Therapies: Trends on Twitter
4.2.1. Historical Trend in Volume of Tweets
4.2.2. Trending Words / Phrases on Twitter
4.2.3. Most Popular Drugs on Twitter
4.2.4. Most Prolific Authors on Twitter
4.2.5. Most Popular Indications and Target Antigens

5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. TCR-based Therapies: Overall Market Landscape
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Popular Target Indications
5.2.5. Analysis by Popular Target Antigen
5.2.6. Analysis by Source of T-Cells
5.2.7. Analysis by Route of Administration
5.2.8. Analysis by Dose Frequency
5.2.9. Analysis by Target Patient Segment
5.2.10. Analysis by Type of Therapy
5.2.11. Key Industry Players: Distribution by Number of Therapies in Pipeline
5.2.12. Key Non-Industry Players: Distribution by Number of Therapies in Pipeline

6. POPULAR TARGET ANTIGEN ANALYSIS
6.1. Chapter Overview
6.2. TCR-based Therapies: Analysis by Popular Target Antigens
6.2.1. Popular Target Antigens related to Hematological Malignancies
6.2.2. Popular Target Antigens related to Solid Tumors 

7. KEY OPINION LEADERS ANALYSIS
7.1. Chapter Overview
7.2. TCR-based Therapies: Key Opinion Leaders
7.2.1. TCR-based Therapies: Most Prominent Key Opinion Leaders

8. TCR-BASED THERAPY PROFILES
8.1. Chapter Overview
8.2. SPEAR T-Cells (Adaptimmune / GlaxoSmithKline)
8.2.1. Therapy Overview
8.2.1.1. Technology Platform
8.2.1.2. Letetresgene Autoleucel / GSK3377794 / NY-ESO SPEAR T-Cell
8.2.1.3. ADP-A2M10 (MAGE-A10) SPEAR T-Cell Therapy
8.2.1.4. ADP-A2AFP SPEAR T-Cell Therapy
8.2.1.5. ADP-A2M4 (MAGE-A4) SPEAR T-Cell Therapy
8.2.2. Current Development Status
8.2.3. Key Clinical Trial Results
8.2.4. Dosage Regimen and Manufacturing

8.3. IMCgp100 (Immunocore)
8.3.1. Therapy Overview
8.3.2. Current Development Status
8.3.3. Key Clinical Trial Results
8.3.4. Dosage Regimen and Manufacturing
8.4. ALT-801 (Altor BioScience)
8.4.1. Therapy Overview
8.4.1.1. History of Development
8.4.2. Current Development Status
8.4.3. Key Clinical Trial Results
8.4.4. Dosage Regimen
8.4.5. Patent Portfolio

8.5. JTCR016 (Juno Therapeutics)
8.5.1. Therapy Overview
8.5.2. Current Development Status
8.5.3. Key Clinical Trial Results
8.5.4. Dosage Regimen and Manufacturing

8.6. CMD-602 / WT1 TCR Therapy (Kuur Therapeutics)
8.6.1. Therapy Overview
8.6.1.1. History of Development
8.6.2. Current Development Status
8.6.3. Key Clinical Trial Results
8.6.4. Dosage Regimen and Manufacturing

8.7. TBI-1301 (Takara Bio)
8.7.1. Therapy Overview
8.7.2. Current Development Status
8.7.3. Key Clinical Trial Results
8.7.4. Dosage Regimen and Manufacturing

8.8. MDG1011 (Medigene)
8.8.1. Therapy Overview
8.8.2. Current Development Status
8.8.3. Key Clinical Trial Results
8.8.4. Dosage Regimen and Manufacturing

9. KEY THERAPEUTIC AREAS FOR TCR-BASED THERAPIES
9.1. Chapter Overview
9.2. Hematological Malignancies
9.2.1. Leukemia and Lymphoma
9.2.1.1. Leukemia: Introduction and Epidemiology
9.2.1.1.1. Acute Myeloid Leukemia (AML)
9.2.1.1.2. Chronic Myeloid Leukemia (CML)
9.2.1.1.3. Acute Lymphocytic Leukemia (ALL)
9.2.1.1.4. Chronic Lymphocytic Leukemia (CLL)
9.2.1.2. Lymphoma: Introduction and Epidemiology
9.2.1.3. Current Treatment Landscape
9.2.1.3.1. Targeted Therapies
9.2.1.4. TCR-based Therapies and Affiliated Research Landscape
9.2.1.4.1. TCR-based Therapies and Leukemia / Lymphoma

9.2.2. Multiple Myeloma
9.2.2.1. Introduction and Epidemiology
9.2.2.2. Current Treatment Landscape
9.2.2.3. TCR-based Therapies and Affiliated Research Landscape

9.3. Solid Tumors
9.3.1. Metastatic Melanoma
9.3.1.1. Introduction and Epidemiology
9.3.1.2. Current Treatment Landscape
9.3.1.3. TCR-based Therapies and Affiliated Research Landscape

9.3.2. Lung Cancer
9.3.2.1. Introduction and Epidemiology
9.3.2.2. Current Treatment Landscape
9.3.2.3. TCR-based Therapies and Affiliated Research Landscape

9.3.3. Pancreatic Cancer
9.3.3.1. Introduction and Epidemiology
9.3.3.2. Current Treatment Landscape
9.3.3.3. TCR-based Therapies and Affiliated Research Landscape
9.3.4. Liver Cancer
9.3.4.1. Current Treatment Landscape
9.3.4.2. TCR-based Therapies and Affiliated Research Landscape

9.3.5. Breast Cancer
9.3.5.1. Introduction and Epidemiology
9.3.5.2. Current Treatment Landscape
9.3.5.3. TCR-based Therapies and Affiliated Research Landscape

9.3.6. Ovarian Cancer
9.3.6.1. Introduction and Epidemiology
9.3.6.2. Current Treatment Landscape
9.3.6.3. TCR-based Therapies and Affiliated Research Landscape

9.3.7. Bladder Cancer
9.3.7.1. Introduction and Epidemiology
9.3.7.2. Current Treatment Landscape
9.3.7.3. TCR-based Therapies and Affiliated Research Landscape

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Types of Partnership Models
10.3. TCR-based Therapies Market: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partner
10.3.4. Most Popular Products
10.3.5. Most Active Industry Players: Analysis by Number of Partnerships
10.3.6. Most Active Non-Industry Players: Analysis by Number of Partnerships
10.3.7. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
10.3.7. Regional Analysis
10.3.8. Intercontinental and Intracontinental Agreements

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. TCR-based Therapies Market: Funding and Investment Analysis
11.3.1. Analysis by Year of Investment
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Most Active Players: Analysis by Number of Funding Instances
11.3.5. Analysis by Type of Investor
11.3.6. Most Active Investors: Analysis by Number of Funding Instances
11.3.7. Regional Analysis by Amount Invested

12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-up
12.4.2. Scale-out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Important Factors Affecting the Process of Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Processes
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Companies with In-House Capabilities
12.11. Contract Manufacturers
12.12. Regulatory Landscape

13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Therapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on the Opinions of Industry Experts
13.4. Reimbursement-related Considerations for T-Cell Therapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Cell Therapies

14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology

14.4. Overall TCR-based Therapies Market, 2021-2030
14.4.1. TCR-based Therapies Market: Distribution by Target Indication
14.4.2. TCR-based Therapies Market: Distribution by Target Antigen
14.4.3. TCR-based Therapies Market: Key Players
14.4.4. TCR-based Therapies Market: Distribution by Geography
14.4.5. Product-wise Sales Forecast

14.5.5.1. GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck)
14.5.5.1.1. Target Patient Population
14.5.5.1.2. Sales Forecast (USD Million)
14.5.5.1.3. Net Present Value (USD Million)
14.5.5.1.4. Value Creation Analysis

14.6.5.2. IMCgp100 (Immunocore)
14.6.5.2.1. Target Patient Population
14.6.5.2.2. Sales Forecast (USD Million)
14.6.5.2.3. Net Present Value (USD Million)
14.6.5.2.4. Value Creation Analysis

14.7.5.3. YT-E001 (China Immunotech)
14.7.5.3.1. Target Patient Population
14.7.5.3.2. Sales Forecast (USD Million)
14.7.5.3.3. Net Present Value (USD Million)
14.7.5.3.4. Value Creation Analysis

14.7.5.4. TBI-1301 (Takara Bio)
14.7.5.4.1. Target Patient Population
14.7.5.4.2. Sales Forecast (USD Million)
14.7.5.4.3. Net Present Value (USD Million)
14.7.5.4.4. Value Creation Analysis
 
14.7.5.5. ALT 801 (Altor BioScience)
14.7.5.5.1. Target Patient Population
14.7.5.5.2. Sales Forecast (USD Million)
14.7.5.5.3. Net Present Value (USD Million)
14.7.5.5.4. Value Creation Analysis

14.7.5.6. JTCR016 (Juno Therapeutics)
14.7.5.6.1. Target Patient Population
14.7.5.6.2. Sales Forecast (USD Million)
14.7.5.6.3. Net Present Value (USD Million)
14.7.5.6.4. Value Creation Analysis

14.7.5.7. LioCyx (Lion TCR)
14.7.5.7.1. Target Patient Population
14.7.5.7.2. Sales Forecast (USD Million)
14.7.5.7.3. Net Present Value (USD Million)
14.7.5.7.4. Value Creation Analysis

14.7.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
14.7.5.8.1. Target Patient Population
14.7.5.8.2. Sales Forecast (USD Million)
14.7.5.8.3. Net Present Value (USD Million)
14.7.5.8.4. Value Creation Analysis

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Summary of Product Website Analysis
15.4. Summary of Patient Support Services and Informative Downloads

15.5. KYMRIAH: Promotional Analysis
15.5.1. Drug Overview
15.5.2. Product Website Analysis
15.5.2.1. Messages for Healthcare Professionals
15.5.2.2. Messages for Patients
15.5.3. Patient Support Services and Informative Downloads
15.5.4. Other Promotional Activities
15.5.4.1. Presence in Conferences

15.6. YESCARTA: Promotional Analysis
15.6.1. Drug Overview
15.6.2. Product Website Analysis
15.6.2.1. Messages for Healthcare Professionals
15.6.2.3. Messages for Patients
15.6.3. Patient Support Services and Informative Downloads
15.6.4. Other Promotional Activities
15.6.4.1. Presence in Conferences

16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Adaptimmune Therapeutics
16.3. Celgene
16.4. Immunocore
16.5. Kuur Therapeutics
16.6. Lion TCR
16.7. Kite Pharma (A Gilead Sciences Company)
16.8. Takara Bio
16.9. Ziopharm Oncology

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Cell Therapies
18.2.1. Interview Transcript: Tim Oldham, Chief Executive Officer
18.3. Kite Pharma
18.3.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
18.4. Lion TCR
18.4.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
18.5. TxCell
18.5.1. Interview Transcript: Miguel Forte, Chief Operating Officer
18.6. Celyad
18.6.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncologys
18.7. Waisman Biomanufacturing
18.7.1. Interview Transcript: Brian Dattilo, Manager of Business Development

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Comparison of Active and Passive Immunotherapies
Figure 3.3 Comparison of Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 TCR-based Therapies: Development Process
Figure 3.7 Challenges Associated with TCR-based Therapies
Figure 3.8 TCR-based Therapies: Benefits and Key Challenges
Figure 4.1 Social Media Analysis: Historical Trend on Twitter, January 2012 - April 2019
Figure 4.2 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 4.3 Social Media Analysis: Most Popular Drugs on Twitter
Figure 4.4 Social Media Analysis: Most Prolific Authors on Twitter
Figure 4.5 Social Media Analysis: Average Number of Likes, Re-tweets and Comments Related to TCR-based Therapies
Figure 4.6 Social Media Analysis: Most Popular Target Indications and Target Antigens
Figure 5.1 TCR-based Therapies: Distribution by Type of Developer
Figure 5.2 TCR-based Therapies: Distribution by Phase of Development
Figure 5.3 TCR-based Therapies: Distribution by Therapeutic Area
Figure 5.4 TCR-based Therapies: Distribution by Popular Target Indications
Figure 5.5 TCR-based Therapies: Distribution by Popular Target Antigens
Figure 5.6 TCR-based Therapies: Distribution by Source of T-Cells
Figure 5.7 TCR-based Therapies: Distribution by Route of Administration
Figure 5.8 TCR-based Therapies: Distribution by Dose Frequency
Figure 5.9 TCR-based Therapies: Distribution by Target Patient Segment
Figure 5.10 TCR-based Therapies: Distribution by Type of Therapy
Figure 5.11 TCR-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 5.12 TCR-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 5.13 TCR-based Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Figure 5.14 TCR-based Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Figure 6.1 TCR-based Therapies: Popular Targets in Hematological Malignancies and Solid
Figure 7.1 TCR-based Therapies: Geographical Distribution of Key Opinion Leaders
Figure 7.2 TCR-based Therapies: Prominent Key Opinion Leaders
Figure 9.1 Leukemia: Classification
Figure 9.2 Leukemia: Global Epidemiological Distribution
Figure 9.3 Lymphoma: Global Epidemiological Distribution
Figure 9.4 Multiple Myeloma: Global Epidemiological Distribution
Figure 9.5 Melanoma: Global Epidemiological Distribution
Figure 9.6 Lung Cancer: Classification
Figure 9.7 Lung Cancer: Global Epidemiological Distribution
Figure 9.8 Pancreatic Cancer: Global Epidemiological Distribution
Figure 9.9 Liver Cancer: Global Epidemiological Distribution
Figure 9.10 Breast Cancer: Global Epidemiological Distribution
Figure 9.11 Ovarian Cancer: Global Epidemiological Distribution
Figure 9.12 Bladder Cancer: Global Epidemiological Distribution
Figure 10.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Figure 10.2 Partnerships and Collaborations: Distribution by Year and Type of Partner, Pre-
Figure 10.3 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015 and 2015-2020
Figure 10.5 Partnerships and Collaborations: Distribution by Individual Products
Figure 10.6 Partnerships and Collaborations: Most Active Industry Players
Figure 10.7 Partnerships and Collaborations: Most Active Non-Industry Players
Figure 10.8 Partnerships and Collaborations: Most Active Contract Manufacturers
Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Figure 10.10 Partnerships and Collaborations: Regional Distribution
Figure 10.11 Partnerships and Collaborations: Intercontinental and Intracontinental
Figure 11.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2013 - 2020 (till October)
Figure 11.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested, Pre-2013 - 2020 (USD Million)
Figure 11.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 11.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 11.5 Most Active Players: Distribution by Number of Funding Instances
Figure 11.6 Funding and Investment: Distribution by Types of Investor
Figure 11.7 Most Active Players: Distribution by Number of Instances
Figure 11.8 Funding and Investment Analysis: Distribution by Geography
Figure 11.9 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Figure 12.1 Steps in Cell Therapy Manufacturing
Figure 12.2 Centralized Manufacturing: Process Model
Figure 12.3 Decentralized Manufacturing: Process Model
Figure 12.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 12.5 Cell Therapy Manufacturing: Challenges and Drivers
Figure 12.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 12.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 12.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 13.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 14.1 Overall TCR-based Therapies Market, 20212030 (USD Billion)
Figure 14.2 TCR-Based Therapies Market: Distribution by Target Indications (USD Billion)
Figure 14.3 TCR-Based Therapies Market: Distribution by Target Antigens (USD Billion)
Figure 14.4 TCR-Based Therapies Market: Key Players (USD Billion)
Figure 14.5 TCR-Based Therapies Market: Distribution by Target Geography (USD Billion)
Figure 14.6 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck): Current
Figure 14.7 GSK3377794 (GlaxoSmithKline / Adaptimmune Therapeutics / Merck) Sales
Figure 14.8 IMCgp100 (Immunocore): Current Status of Development
Figure 14.9 IMCgp100 (Immunocore) Sales Forecast, till 2030 (USD Million)
Figure 14.10 YT-E001 (China Immunotech): Current Status of Development
Figure 14.11 YT-E001 (China Immunotech) Sales Forecast, till 2030 (USD Million)
Figure 14.12 TBI-1301 (Takara Bio): Current Status of Development
Figure 14.13 TBI-1301 (Takara Bio) Sales Forecast, till 2030 (USD Million)
Figure 14.14 ALT 801 (Altor BioScience): Current Status of Development
Figure 14.15 ALT 801 (Altor BioScience) Sales Forecast, till 2030 (USD Million)
Figure 14.16 JTCR016 (Juno Therapeutics): Current Status of Development
Figure 14.17 JTCR016 (Juno Therapeutics) Sales Forecast, till 2030 (USD Million)
Figure 14.18 LioCyx (Lion TCR): Current Status of Development
Figure 14.19 LioCyx (Lion TCR) Sales Forecast, till 2030 (USD Million)
Figure 14.20 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE
Figure 14.21 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE
Figure 15.1 Channels Used for Promotional Campaigns
Figure 15.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 15.3 Promotional / Marketing Strategy: Patient Support Services and Informative
Figure 15.4 Product Website Analysis: KYMRIAH®, Messages for Healthcare Professionals
Figure 15.5 Product Website Analysis: KYMRIAH®, Messages for Patients
Figure 15.6 Product Website Analysis: KYMRIAH®, Patient Support Program
Figure 15.7 KYMRIAH®, Presence in Conferences
Figure 15.8 Product Website Analysis: YESCARTA®, Messages for Healthcare
Figure 15.9 Product Website Analysis: YESCARTA®, Messages for Patients
Figure 15.10 Product Website Analysis: YESCARTA®, Kite Konnect
Figure 15.11 Product Website Analysis: YESCARTA®, Platform for Reporting Adverse
Figure 15.12 YESCARTA®, Presence in Conferences
Figure 17.1 Concluding Remarks: Overall Market Landscape
Figure 17.3 Concluding Remarks: Partnerships & Collaborations and Funding and Investment
Figure 17.4 Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Types of Immunotherapies and Their Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.3 Comparison of CAR-T Cell and TCR-based Therapies: Key Differences
Table 5.1 TCR-based Therapies: Clinical Pipeline
Table 5.2 TCR-based Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 5.3 TCR-based Therapies: Information on Sponsor, Type of Developer, Target Antigen, Target Indication and Therapeutic Area
Table 5.4 TCR-based Therapies: Preclinical Pipeline
Table 7.1 TCR-based Therapies: Principle Investigators
Table 8.1 Letetresgene Autoleucel / GSK3377794 / NY-ESO SPEAR T-Cell: Clinical Studies
Table 8.2 ADP-A2M10 (MAGE-A10) SPEAR T-Cell Therapy: Clinical Studies
Table 8.3 ADP-A2AFP SPEAR T-Cell Therapy: Clinical Studies
Table 8.4 ADP-A2M4 (MAGE-A4) SPEAR T-Cell Therapy: Clinical Studies
Table 8.5 Letetresgene Autoleucel / GSK3377794 / NY-ESO TCR SPEAR T-Cell: Clinical Trial Endpoints
Table 8.6 A2M10 / ADP-A2M4 / ADP-A2AFP: Clinical Trial Endpoints
Table 8.7 IMCgp100: Clinical Studies
Table 8.8 IMCgp100: Clinical Trial Endpoints
Table 8.9 ALT-801: Clinical Studies
Table 8.10 ALT-801: Clinical Trial Endpoints
Table 8.11 JTCR016: Clinical Studies
Table 8.12 JTCR016: Clinical Trial Endpoints
Table 8.13 WT1 TCR: Clinical Studies
Table 8.14 WT1 TCR: Clinical Trial Endpoints
Table 8.15 TBI-1301: Current Status of Development
Table 8.16 TBI-1301: Clinical Trial Endpoints
Table 8.17 MDG1011: Clinical Studies
Table 8.18 MDC1011: Clinical Trial Endpoints
Table 8.19 Phase I/II or Phase II TCR-based Therapies being Developed by Industry Players
Table 9.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
Table 9.2 Leukemia: List of Marketed Targeted Therapeutics
Table 9.3 Lymphoma: List of Marketed Targeted Therapeutics
Table 9.3 Multiple Myeloma: List of Marketed Targeted Therapeutics
Table 9.4 TCR-based Therapies: Targets under Investigation for Multiple Myeloma
Table 9.5 Melanoma: List of Marketed Targeted Therapeutics
Table 9.6 Lung Cancer: List of Marketed Targeted Therapeutics
Table 9.7 TCR-based Therapies: Targets under Investigation for Lung Cancer
Table 9.8 Pancreatic Cancer: List of Marketed Targeted Therapeutics
Table 9.9 Liver Cancer: List of Marketed Targeted Therapeutics
Table 9.10 TCR-based Therapies: Targets under Investigation for Liver Cancer
Table 9.11 Breast Cancer: List of Marketed Targeted Therapeutics
Table 9.12 TCR-based Therapies: Targets under Investigation for Breast Cancer
Table 9.13 Ovarian Cancer: List of Marketed Targeted Therapeutics
Table 9.14 Bladder Cancer: List of Marketed Targeted Therapeutics
Table 10.1 TCR-based Therapies Market: List of Partnerships and Collaborations, 2005-2020 (till October)
Table 11.1 TCR-based Therapies: Funding and Investments, 2000-2020 (till October)
Table 11.2 TCR-based Therapies: Summary of Investments
Table 12.1 Assessment Strategies for Different Manufacturing Processes
Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 12.3 Cell Therapy Manufacturing: Companies with In-house Capabilities
Table 12.4 Cell Therapy Manufacturing: Contract Manufacturers
Table 13.1 Price of Marketed Gene / Cell Therapies
Table 13.2 Price of Marketed Targeted Drugs
Table 13.3 TCR-based Therapies: Expert Opinions on Pricing
Table 13.4 TCR-based Therapies: Reimbursement Landscape
Table 14.1 TCR-based Therapies: List of Forecasted Molecules
Table 14.2 GSK3377794 (GlaxoSmithKline/ Adaptimmune Therapeutics/ Merck): Net Present Value (USD Million)
Table 14.3 GSK3377794 (GlaxoSmithKline/ Adaptimmune Therapeutics/ Merck): Value Creation Analysis (USD Million)
Table 14.4 IMCgp100 (Immunocore): Net Present Value (USD Million)
Table 14.5 IMCgp100 (Immunocore): Value Creation Analysis (USD Million)
Table 14.6 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 14.7 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 14.8 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 14.9 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 14.10 ALT 801 (Altor BioScience): Net Present Value (USD Million)
Table 14.11 ALT 801 (Altor BioScience): Value Creation Analysis (USD Million)
Table 14.12 JTCR016 (Juno Therapeutics): Net Present Value (USD Million)
Table 14.13 JTCR016 (Juno Therapeutics): Value Creation Analysis (USD Million)
Table 14.14 LioCyx (Lion TCR): Net Present Value (USD Million)
Table 14.15 LioCyx (Lion TCR): Value Creation Analysis (USD Million)
Table 14.16 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 14.17 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 15.1 Kymriah: Drug Overview
Table 15.2 Yescarta: Drug Overview
Table 16.1 Adaptimmune Therapeutics: Company Profile
Table 16.2 Celgene: Company Profile
Table 16.3 Immunocore: Company Profile
Table 16.4 Kite Pharma: Company Profile
Table 16.5 Kuur Therapeutics: Company Profile
Table 16.6 Lion TCR: Company Profile
Table 16.7 Takara Bio: Company Profile
Table 16.8 Ziopharm Oncology: Company Profile
Table 19.1 TCR-based Therapies: Distribution by Type of Developer
Table 19.2 TCR-based Therapies: Distribution by Phase of Development
Table 19.3 TCR-based Therapies: Distribution by Target Therapeutic Area
Table 19.4 TCR-based Therapies: Distribution by Popular Target Indications
Table 19.5 TCR-based Therapies: Distribution by Popular Target Antigens
Table 19.6 TCR-based Therapies: Distribution by Source of T-Cells
Table 19.7 TCR-based Therapies: Distribution by Route of Administration
Table 19.8 TCR-based Therapies: Distribution by Dose Frequency
Table19.9 TCR-based Therapies: Distribution by Target Patient Segment
Table 19.10 TCR-based Therapies: Distribution by Type of Therapy
Table 19.11 TCR-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 19.12 TCR-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 19.13 TCR-based Therapies: Active Non-Industry Players by Number of Therapies in Clinical Development
Table 19.14 TCR-based Therapies: Active Non-Industry Players by Number of Therapies in Preclinical Development
Table 19.15 TCR-based Therapies: Geographical Distribution of Key Opinion Leaders
Table 19.16 TCR-based Therapies: Prominent Key Opinion Leaders
Table 19.17 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2005-2020
Table 19.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.19 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015 and 2015-2020
Table 19.20 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 19.21 Partnerships and Collaborations: Distribution by Year and Type of Product
Table 19.22 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.23 Partnerships and Collaborations: Distribution by Type of Product and Type of Player
Table 19.24 Partnerships and Collaborations: Distribution by Individual Products
Table 19.25 Partnerships and Collaborations: Most Active Industry Players
Table 19.26 Partnerships and Collaborations: Most Active Non-Industry Players
Table 19.27 Partnerships and Collaborations: Most Active Contract Manufacturers
Table 19.28 Partnerships and Collaborations: Intercontinental and Intracontinental Manufacturing Agreements
Table 19.29 Partnerships and Collaborations: Regional Distribution
Table 19.30 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 19.31 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2013 - 2020 (Till October)
Table 19.32 Funding and Investment Analysis: Distribution by Cumulative Amount Invested, Pre-2013 - 2020 (USD Million)
Table 19.33 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 19.34 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 19.35 Funding and Investments: Distribution by Amount Invested across Different Types of Therapies, Pre-2012 - 2020 (Till October)
Table 19.36 Most Active Players: Distribution by Number of Instances
Table 19.37 Funding and Investments: Distribution by Types of Investor
Table 19.38 Most Active Players: Distribution by Number of Instances
Table 19.39 Funding and Investment Analysis: Distribution by Geography
Table 19.40 Funding and Investment Analysis: Distribution of Amount Invested across Different Countries (USD Million)
Table 19.41 Overall TCR-based Therapies Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 19.42 TCR-based Therapies Market: Distribution by Target Indications, 2025 and 2030 (USD Billion)
Table 19.43 TCR-based Therapies Market: Distribution by Target Antigens, 2025 and 2030 (USD Billion)
Table 19.44 TCR-based Therapies Market: Key Players, 2025 and 2030 (USD Billion)
Table 19.45 TCR-based Therapies Market: Distribution by Geography, 2025 and 2030 (USD Billion)
Table 19.46 GSK3377794 (GlaxoSmithKline/ Adaptimmune Therapeutics/ Merck) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030: (USD Million)
Table 19.47 IMCgp100 (Immunocore) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 19.48 YT-E001 (China Immunotech) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 19.49 TBI-1301 (Takara Bio) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 19.50 ALT-801 (Altor Bioscience) Sales Forecast, Conservative, Base and Scenarios, till 2030 (USD Million)
Table 19.51 JTCR016 (Juno Therapeutics) Sales Forecast, Conservative, Base and Optimistic
Table 19.52 LioCyx (Lion TCR) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)
Table 19.53 LMBP2-specific TCR-T (TCR CURE Biopharma Technology) Sales Forecast, Conservative, Base and Optimistic Scenarios, till 2030 (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  1. 6 Dimensions Capital
  2. Aditya Birla Capital
  3. AbVitro
  4. Acorn Pacific Ventures
  5. Adage Capital Management
  6. Adaptimmune Therapeutics
  7. Adicet Bio
  8. Agency for Science, Technology and Research (A*STAR)
  9. Agent Capital
  10. AgenTus Therapeutics
  11. Aisling Capital
  12. AJU IB Investment
  13. Alaska Permanent Fund
  14. Albert Einstein College of Medicine 
  15. Alexandria Real Estate Equities
  16. Alexandria Venture Investments
  17. Alex's Lemonade Stand Foundation (ALSF)
  18. Alpine Immune Sciences
  19. Alta Partners
  20. Altor BioScience 
  21. Amgen
  22. Amgen Ventures
  23. Andera Partners
  24. Andreessen Horowitz
  25. ARCH Venture Partners
  26. Arix Bioscience
  27. ArrowMark Partners
  28. Astellas Pharma
  29. Astellas Venture Management
  30. AstraZeneca
  31. AT Impf
  32. Athenex
  33. Atlas Venture
  34. Atreca
  35. Autolus
  36. Alumni Ventures Group
  37. Baader Bank
  38. Baxalta Ventures
  39. Baxter Ventures
  40. Baylor College of Medicine
  41. Be The Match BioTherapies
  42. Beijing 302 Hospital
  43. Bellicum Pharmaceuticals 
  44. Berlin Institute of Health
  45. Bessemer Venture Partners
  46. Bezos Expeditions
  47. Bill & Melinda Gates Foundation 
  48. Biomedical Catalyst 
  49. BioNTech
  50. bluebird bio
  51. BNH Investment
  52. Boehringer Ingelheim Venture Fund
  53. Boxer Capital
  54. Brace Pharma Capital
  55. BrightEdge
  56. BVCF 
  57. California Institute for Regenerative Medicine (CIRM) 
  58. California Institute of Technology
  59. Cancer Prevention and Research Institute of Texas
  60. Cancer Research UK
  61. Captain T Cell
  62. Cardiff University
  63. Cartherics
  64. Cell Design Labs
  65. Cell and Gene Therapy Catapult
  66. Cellular Biomedicine Group
  67. Cellular Therapeutics
  68. Changhai Hospital
  69. Charité – Universitätsmedizin Berlin
  70. China Immunotech (Beijing) Biotechnology
  71. Cogent Biosciences
  72. Cormorant Asset Management
  73. Cowen
  74. Cryoport
  75. CRC for Cell Therapy Manufacturing
  76. Curative Ventures
  77. Cytovant Sciences
  78. Dana-Farber Cancer Institute
  79. Direct Selling Association of Malaysia (DSAM)
  80. Ditch Plains Capital Management
  81. DUMAC 
  82. Duke-NUS Medical School
  83. Earle A. Chiles Research Institute
  84. EcoR1 Capital 
  85. Editas Medicine
  86. Edmond de Rothschild Investment Partners 
  87. Efung Capital 
  88. Ehime University
  89. Eli Lilly
  90. Eureka Therapeutics
  91. Eutilex
  92. F2 Ventures
  93. F-Prime Capital
  94. Fidelity Management & Research
  95. First Affiliated Hospital of Jinan University
  96. Fiverings 
  97. Foresite Capital
  98. Fosun Pharmaceutical
  99. F-Prime Capital
  100. Franklin Templeton
  101. Fred Hutchinson Cancer Research Center
  102. Fudan University
  103. Fujian Provincial Cancer Hospital, Fujian Medical University
  104. Fujita Health University
  105. Gadeta
  106. GE Healthcare
  107. Genmab
  108. Federal Ministry of Education and Research GigaGen
  109. GlaxoSmithKline
  110. Glycostem Therapeutics
  111. GP Capital
  112. Gritstone Oncology
  113. Grower Venture Capital
  114. Guangdong Xiangxue Precision Medical Technology
  115. Guangzhou FineImmune Biotechnology
  116. Guangzhou Institute of Respiratory Disease
  117. GV
  118. Haitong International Securities
  119. Hebei Senlang Biotechnology
  120. Hebei Yanda Lu Daopei Hospital
  121. Helmholtz Zentrum München
  122. Henan Provincial People's Hospital
  123. HiFiBiO Therapeutics
  124. Hillhouse Capital Group
  125. dievini Hopp BioTech
  126. Howard Hughes Medical Institute
  127. Immatics
  128. Immunocore
  129. Imperial Innovations
  130. Innovate UK
  131. Intellia Therapeutics
  132. Intrexon 
  133. Invesco Perpetual
  134. Invus
  135. IRICoR
  136. Japan Science and Technology Agency (JST)
  137. Jebsen Capital
  138. Jianxin Capital
  139. Jonsson Comprehensive Cancer Center
  140. Juno Therapeutics
  141. JW Therapeutics
  142. Karolinska Institutet
  143. Kite Pharma
  144. Kleiner Perkins
  145. Kuur Therapeutics
  146. Laurion Capital Management
  147. Legend Biotech
  148. Leiden University Medical Center 
  149. Level One Partners
  150. Life Technologies
  151. Lilly Asia Ventures
  152. Lion TCR
  153. Longwood Fund
  154. Loyola University Medical Center
  155. Lucion Venture Capital Group 
  156. Lyell Immunopharma
  157. Malin
  158. Massachusetts General Hospital 
  159. MaSTherCell
  160. Matrix Capital Management
  161. Max Delbrück Centre for Molecular Medicine
  162. MaxCyte
  163. Medicxi Ventures
  164. Medigene
  165. MedImmune
  166. Memorial Sloan Kettering Cancer Center
  167. Merck
  168. Merlin Nexus
  169. Mie University
  170. Miller Value Partners
  171. Miltenyi Biotec
  172. Mirae Asset Financial Group
  173. Mission Bay Capital
  174. MPM Capital
  175. MSD Partners
  176. Nagoya University
  177. NantKwest
  178. National Cancer Institute
  179. National Heart, Lung, and Blood Institute
  180. National Institute of Allergy and Infectious Diseases (NIAID)
  181. National Institute of Cancer Prevention and Research
  182. National Institutes of Health
  183. New Enterprise Associates
  184. New Leaf Ventures
  185. New York State Stem Cell Science Program (NYSTEM)
  186. Nextech Invest
  187. NIH Small Business Innovation Research (SBIR)
  188. Noile-Immune Biotech
  189. Novartis
  190. Novartis Institutes for BioMedical Research (NIBR)
  191. Novartis Venture Fund
  192. Novo Nordisk
  193. OCV Partners
  194. OrbiMed
  195. OrbiMed Advisors
  196. Osage University Partners
  197. Oslo University Hospital
  198. Ospedale Pediatrico Bambino Gesù (OPBG)
  199. Otsuka Pharmaceutical
  200. Oxford BioMedica
  201. PACT Pharma
  202. Panacea Ventures
  203. Parker Institute for Cancer Immunotherapy
  204. Penn Medicine
  205. Perceptive Bioscience Investments
  206. Perspective Advisors
  207. Phio Pharmaceuticals
  208. Ping An Ventures
  209. Pitango Venture Capital
  210. Platinum Asset Management
  211. Pontifax Venture Capital
  212. Pontifax AgTech
  213. POSCO Capital
  214. Precigen
  215. Precision BioSciences
  216. Progenitor Cell Therapy
  217. Providence Health & Services
  218. QVT Financial
  219. RA Capital Management
  220. Redmile Group
  221. RedoxTherapeis
  222. Regeneron
  223. Remeditex Ventures
  224. Ridgeback Capital Management
  225. Roche
  226. Rock Springs Capital
  227. Roswell Park Cancer Institute
  228. RTW Investments
  229. RXi Pharmaceuticals
  230. Sabby Management
  231. Samsara BioCapital
  232. Sanofi-Genzyme BioVentures
  233. SVB Leerink
  234. Seattle Children’s Research Institute
  235. Seattle Genetics
  236. Second Affiliated Hospital of Guangzhou Medical University
  237. Sectoral Asset Management
  238. Shanghai Zhongshan Hospital
  239. Shenzhen BinDeBio
  240. Shenzhen Institute for Innovation and Translational Medicine
  241. Shenzhen Second People's Hospital
  242. Sirona Capital
  243. Smilegate Investment
  244. Square 1 Bank
  245. Stage Cell Therapeutics 
  246. Statcom 
  247. Steam Athena Capital
  248. Structured Immunity
  249. Sun Yat-sen University
  250. Syncona
  251. Syno Capital
  252. Tactiva Therapeutics
  253. Takara Bio
  254. TCRCure Biopharma
  255. TCR2 Therapeutics
  256. Tekla Capital Management
  257. Leukemia and Lymphoma Society
  258. The Netherlands Cancer Institute
  259. The Texas Emerging Technology Fund
  260. The University of California, Los Angeles (UCLA)
  261. The University of Chicago 
  262. The University of Texas Health Science Center
  263. The University of Texas MD Anderson Cancer Center
  264. The University of Tokyo Hospital
  265. Thermo Fisher Scientific 
  266. Tianjin Medical University
  267. T-knife
  268. Tmunity Therapeutics
  269. Touchstone Innovations
  270. Trout Capital 
  271. TScan Therapeutics
  272. Universal Cells
  273. University College London
  274. University Health Network
  275. University Medical Center Utrecht
  276. University of California San Francisco
  277. University of Connecticut
  278. University of Lausanne
  279. University of Montreal
  280. University of Oxford
  281. University of Pennsylvania
  282. University of Southern California
  283. Utrecht Holdings
  284. venBio
  285. Venrock
  286. Versant Ventures
  287. VI Ventures
  288. Vineti
  289. Vivo Capital
  290. Wellcome Trust
  291. Wellington Management
  292. Wellington Partners
  293. Westlake Ventures 
  294. Westlake Village BioPartners
  295. White Rock Capital Partners 
  296. Woodford Investment Management 
  297. Wuhan Dangdai Science & Technology Industries 
  298. WuXi AppTec
  299. X-Body
  300. Xiangxue Life Sciences
  301. Xiangxue Pharmaceutical
  302. Xinqiao Hospital 
  303. Yeshiva University
  304. Zelluna Immunotherapy
  305. Zhejiang Huacheng Group
  306. Zhejiang Huahai Pharmaceutical 
  307. Zhejiang University
  308. Zhujiang Hospital
  309. Ziopharm Oncology

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com